Kevin Ostrander

Kevin Ostrander has extensive experience in business development and leadership roles in the pharmaceutical industry. Kevin is currently serving as the Chief Business Officer at Corium, Inc. Prior to this, they held the position of Vice President of Business Development at ApiJect, and SVP of Business Development at BioDelivery Sciences International. Kevin also served as the Head of North America Business Development at Glenmark Pharmaceuticals, and Executive Director of Business Development and Licensing at Sandoz. Kevin has held various other leadership roles in companies such as Mylan Specialty, Eurand, Watson Pharmaceuticals, NexMed Pharmaceuticals, and Cardinal Health.

Kevin Ostrander has a diverse educational background. Kevin holds an M.B.A. in International Business from the Saint Joseph's University - Erivan K. Haub School of Business. Additionally, they earned a B.S. in Biology/Chemistry from the University at Albany, SUNY. Kevin furthered their education by obtaining an M.S. in Regulatory Affairs/Quality Assurance from the Temple University School of Pharmacy.